DFV890
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Familial Cold Autoinflammatory Syndrome
Conditions
Familial Cold Autoinflammatory Syndrome
Trial Timeline
Sep 20, 2021 → May 5, 2023
NCT ID
NCT04868968About DFV890
DFV890 is a phase 2 stage product being developed by Novartis for Familial Cold Autoinflammatory Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT04868968. Target conditions include Familial Cold Autoinflammatory Syndrome.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05552469 | Phase 1 | Active |
| NCT04868968 | Phase 2 | Completed |
Competing Products
20 competing products in Familial Cold Autoinflammatory Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Bromocriptine Mesilate + Placebos | Towa Pharmaceutical | Phase 1/2 | 40 |
| SHR-1209 | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Rosuvastatin 20mg + Placebo | AstraZeneca | Phase 3 | 77 |
| rosuvastatin calcium + rosuvastatin calcium + rosuvastatin calcium | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin + Placebo | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin 20mg | AstraZeneca | Phase 3 | 77 |
| AZD0780 + Placebo | AstraZeneca | Phase 3 | 77 |
| Anacetrapib + Placebo for anacetrapib | Merck | Phase 3 | 77 |
| Statins and Ezetimibe | Merck | Pre-clinical | 23 |
| Comparator: niacin (+) laropiprant (MK0524A) + Comparator: placebo | Merck | Phase 3 | 77 |
| MK-0524A + MK-0524A | Merck | Phase 1 | 33 |
| Enlicitide Decanoate + Placebo | Merck | Phase 2/3 | 65 |
| Inclisiran + Placebo | Novartis | Phase 3 | 77 |
| Canakinumab | Novartis | Phase 2 | 52 |
| Inclisiran Sodium for injection + Placebo + Placebos | Novartis | Phase 3 | 77 |
| LCQ908 + Placebo | Novartis | Phase 3 | 77 |
| Inclisiran | Novartis | Phase 3 | 77 |
| Inclisiran + Placebo | Novartis | Phase 3 | 77 |
| Fluvastatin | Novartis | Phase 3 | 77 |